We are live on ! Find out more
AQST icon

Aquestive Therapeutics

35 hedge funds and large institutions have $17M invested in Aquestive Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0.02% more ownership

Funds ownership: 27.56% → 27.58% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less capital inflows, than outflows

Capital inflows: $630K | Capital outflows: $643K

3% less funds holding

Funds holding: 36 → 35 (-1)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Holders
35
Holders Change
-1
Holders Change %
-2.78%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
7
Reduced
6
Closed
9
Calls
$20​K
Puts
–
Net Calls
+$20​K
Net Calls Change
-⁠$31​K

AQST Hedge Fund Activity: Q1 2023 in Review

35 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2023, worth a combined $17M — up 26% from $13.5M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of AQST and 8 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 7 added.

The largest buyer was Millennium Management, adding an estimated $222K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $457K sold.

  • 35 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2023, down from 36 in Q4 2022.
  • Funds reported $17M of Aquestive Therapeutics stock for Q1 2023, up 26% quarter-over-quarter.
  • 8 funds opened new Aquestive Therapeutics positions in Q1 2023 and 9 closed out, a net change of -1 holder.
  • The largest Aquestive Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $222K added.
  • The largest Aquestive Therapeutics seller in Q1 2023 was Schonfeld Strategic Advisors, an estimated $457K sold.

Based on aggregated 13F filings for Q1 2023.